トポイソメラーゼI阻害剤の世界市場レポート 2025年

トポイソメラーゼI阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で69億5,000万米ドルに成長します。予測期間中の成長は、がん罹患率の増加、研究開発の拡大、がん治療選択肢に対する意識の高まり、高齢化、がん研究に対する政府資金の増加などに起因すると考えられます。この期間に予想される主要動向には、ゲノムと個別化医療の進展、経口製剤の開発、併用治療の有効性の向上、ジェネリック医薬品の開発、官民連携の増加などがあります。

がんの有病率の増加は、近い将来トポイソメラーゼI阻害剤市場を大きく押し上げると予想されます。がんは、異常細胞の無秩序な増殖と拡散によって定義される疾患群であり、死亡を含む深刻な健康合併症を引き起こす可能性があります。がん患者の増加は、食生活の乱れ、運動不足、タバコの使用など、生活習慣に関連する危険因子の増加と関連しており、これらすべてががん罹患率の上昇に寄与しています。トポイソメラーゼI阻害剤は、がん細胞のDNA複製プロセスを阻害することによってDNA損傷を引き起こし、細胞分裂を停止させ、細胞死を誘導することにより、がん治療に使用されます。例えば、2024年2月、世界保健機関（WHO）は、2050年までに新たに3,500万人以上のがん患者が発生し、2022年に予想された2,000万人から77％増加すると予測しました。このようながん患者の急増は、トポイソメラーゼI阻害剤市場の成長にとって重要な促進要因となります。

トポイソメラーゼI阻害剤市場の主要企業は、抗体の標的化能力を活用して薬剤耐性を克服する抗体薬剤複合体（ADC）などの市場の開拓に注力しています。ADCは、抗体を細胞傷害性薬剤に結合させる特殊ながん治療であり、健康な組織へのダメージを最小限に抑えながら、薬剤をがん細胞に確実に直接送達します。例えば、2024年7月、カナダに本社を置くバイオテクノロジー企業であるザイメワークス社は、米国食品医薬品局（FDA）がZW191の治験新薬（IND）申請を承認したと発表しました。この革新的なADCは、葉酸受容体a（FRa）を標的とし、トポイソメラーゼI阻害剤（TOPO1i）を送達します。ZW191は、先進的なTOPO1iベースのペイロード技術であるZD06519を組み込んだ、当社独自の薬剤複合体プラットフォームを用いて開発されました。ZW191は、主に卵巣がんやその他の婦人科がん、非小細胞肺がん（NSCLC）を含むFRa発現腫瘍を標的とします。この薬剤は、安全性と有効性を最適化するために8種類の薬剤抗体比（DAR）で設計され、忍容性と治療効果のバランスを目指しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のトポイソメラーゼI阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のトポイソメラーゼI阻害剤市場：成長率分析
• 世界のトポイソメラーゼI阻害剤市場の実績：規模と成長、2019～2024年
• 世界のトポイソメラーゼI阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界のトポイソメラーゼI阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のトポイソメラーゼI阻害剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カンプトテシン誘導体
• 非カンプトテシン
• 世界のトポイソメラーゼI阻害剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射剤
• その他
• 世界のトポイソメラーゼI阻害剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他
• 世界のトポイソメラーゼI阻害剤市場、カンプトテシン誘導体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• イリノテカン
• トポテカン
• 世界のトポイソメラーゼI阻害剤市場、非カンプトテシンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• LMP-400
• インデノイソキノリン

第7章 地域別・国別分析

• 世界のトポイソメラーゼI阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のトポイソメラーゼI阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• トポイソメラーゼI阻害剤市場：競合情勢
• トポイソメラーゼI阻害剤市場：企業プロファイル
  • Pfizer Inc.
  • Nektar Therapeutics
  • AstraZeneca PLC
  • Novartis AG
  • Fresenius Kabi AG

第31章 その他の大手企業と革新的企業

• Merck KGaA
• BioNTech SE
• Daiichi Sankyo Company Limited
• Ipsen Pharma S.A.S.
• Purdue Pharma L.P.
• Zymeworks Inc.
• Sagent Pharmaceuticals Inc.
• Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
• Debiopharm Group SA
• Harbour BioMed Therapeutics Limited
• Bio-Thera Solutions Ltd.
• Gibson Oncology LLC
• TopoGEN Inc.
• DualityBio Inc.
• Iksuda Therapeutics Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• トポイソメラーゼI阻害剤市場、2029年：新たな機会を提供する国
• トポイソメラーゼI阻害剤市場、2029年：新たな機会を提供するセグメント
• トポイソメラーゼI阻害剤市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Topoisomerase I inhibitors are a class of therapeutic agents that interfere with the activity of topoisomerase I, an enzyme responsible for relieving the torsional strain that occurs during DNA replication and transcription. These inhibitors work by binding to the enzyme-DNA complex, preventing the re-ligation of DNA strands after the enzyme induces a temporary break. Disruption of topoisomerase I activity leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in rapidly dividing cells.

The main types of topoisomerase I inhibitors include camptothecin derivatives and non-camptothecin-based inhibitors. Camptothecin derivatives are drugs developed from camptothecin, a natural compound extracted from the Chinese tree Camptotheca acuminata. These inhibitors can be administered through oral, injectable, and other routes and are commonly used in hospitals, clinics, and other healthcare settings.

The topoisomerase I inhibitors market research report is one of a series of new reports from The Business Research Company that provides topoisomerase I inhibitors market statistics, including topoisomerase I inhibitors industry global market size, regional shares, competitors with a topoisomerase I inhibitors market share, detailed topoisomerase I inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the topoisomerase I inhibitors industry. This topoisomerase I inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The topoisomerase I inhibitors market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to improvements in healthcare infrastructure, rising global healthcare expenditure, higher cancer diagnosis rates, a growing focus on precision oncology, and increased funding for biotech startups.

The topoisomerase I inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to the increasing prevalence of cancer, expanding research and development, rising awareness of cancer treatment options, an aging population, and increasing government funding for oncology research. Key trends expected during this period include advancements in genomics and personalized medicine, the development of oral formulations, improved efficacy of combination treatments, the development of generic topoisomerase I inhibitors, and increased public-private collaborations.

The growing prevalence of cancer is expected to significantly boost the topoisomerase I inhibitors market in the near future. Cancer, a group of diseases defined by the uncontrolled growth and spread of abnormal cells, can result in serious health complications, including death. The rise in cancer cases is linked to increasing lifestyle-related risk factors such as poor diet, insufficient physical activity, and tobacco use, all contributing to higher cancer incidence. Topoisomerase I inhibitors are used in cancer treatment by disrupting the DNA replication process in cancer cells, causing DNA damage that halts cell division and induces cell death. For example, in February 2024, the World Health Organization (WHO) projected that by 2050, over 35 million new cancer cases will be diagnosed, a 77% increase from the 20 million expected in 2022. This surge in cancer cases will be a key driver for the growth of the topoisomerase I inhibitors market.

Leading companies in the topoisomerase I inhibitors market are concentrating on developing advanced treatments such as antibody-drug conjugates (ADCs) to overcome drug resistance by leveraging the targeting capabilities of antibodies. ADCs are specialized cancer therapies that attach antibodies to cytotoxic drugs, ensuring that the drug is delivered directly to cancer cells while minimizing damage to healthy tissue. For instance, in July 2024, Zymeworks Inc., a biotechnology company based in Canada, announced that the U.S. Food and Drug Administration (FDA) approved its investigational new drug (IND) application for ZW191. This innovative ADC targets the folate receptor-a (FRa) and delivers a topoisomerase I inhibitor (TOPO1i). ZW191 was developed using the company's proprietary drug conjugate platforms, incorporating the advanced TOPO1i-based payload technology, ZD06519. It primarily targets FRa-expressing tumors, including ovarian and other gynecological cancers, as well as non-small cell lung cancer (NSCLC). The drug was designed with eight drug-antibody ratios (DAR) to optimize safety and efficacy, aiming for a balance of tolerability and therapeutic benefit.

In May 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio for $1.8 billion. This acquisition bolstered Genmab's position in the targeted cancer therapy market, with a particular focus on ovarian and other solid tumors. This move aligns with Genmab's strategy to expand its portfolio of innovative cancer treatments. ProfoundBio, a U.S.-based company, specializes in the manufacturing of topoisomerase I inhibitors.

Major players in the topoisomerase i inhibitors market are Pfizer Inc., Nektar Therapeutics, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Merck KGaA, BioNTech SE, Daiichi Sankyo Company Limited, Ipsen Pharma S.A.S., Purdue Pharma L.P., Zymeworks Inc., Sagent Pharmaceuticals Inc., Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Debiopharm Group SA, Harbour BioMed Therapeutics Limited, Bio-Thera Solutions Ltd., Gibson Oncology LLC, TopoGEN Inc., DualityBio Inc., Iksuda Therapeutics Ltd.

North America was the largest region in the topoisomerase I inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in topoisomerase I inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the topoisomerase I inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The topoisomerase I inhibitors market consists of sales of chemotherapy drugs, diagnostic kits, intravenous infusion bags and combination therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Topoisomerase I Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on topoisomerase i inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for topoisomerase i inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The topoisomerase i inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Camptothecin Derivatives; Non-Camptothecin
• 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 3) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Camptothecin Derivatives: Irinotecan; Topotecan
• 2) By Non-Camptothecin: LMP-400; Indenoisoquinolines
• Companies Mentioned: Pfizer Inc.; Nektar Therapeutics; AstraZeneca PLC; Novartis AG; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Topoisomerase I Inhibitors Market Characteristics

3. Topoisomerase I Inhibitors Market Trends And Strategies

4. Topoisomerase I Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Topoisomerase I Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Topoisomerase I Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Topoisomerase I Inhibitors Market Growth Rate Analysis
• 5.4. Global Topoisomerase I Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Topoisomerase I Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Topoisomerase I Inhibitors Total Addressable Market (TAM)

6. Topoisomerase I Inhibitors Market Segmentation

• 6.1. Global Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Camptothecin Derivatives
• Non-Camptothecin
• 6.2. Global Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes Of Administration
• 6.3. Global Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 6.4. Global Topoisomerase I Inhibitors Market, Sub-Segmentation Of Camptothecin Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Irinotecan
• Topotecan
• 6.5. Global Topoisomerase I Inhibitors Market, Sub-Segmentation Of Non-Camptothecin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• LMP-400
• Indenoisoquinolines

7. Topoisomerase I Inhibitors Market Regional And Country Analysis

• 7.1. Global Topoisomerase I Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Topoisomerase I Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Topoisomerase I Inhibitors Market

• 8.1. Asia-Pacific Topoisomerase I Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Topoisomerase I Inhibitors Market

• 9.1. China Topoisomerase I Inhibitors Market Overview
• 9.2. China Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Topoisomerase I Inhibitors Market

• 10.1. India Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Topoisomerase I Inhibitors Market

• 11.1. Japan Topoisomerase I Inhibitors Market Overview
• 11.2. Japan Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Topoisomerase I Inhibitors Market

• 12.1. Australia Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Topoisomerase I Inhibitors Market

• 13.1. Indonesia Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Topoisomerase I Inhibitors Market

• 14.1. South Korea Topoisomerase I Inhibitors Market Overview
• 14.2. South Korea Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Topoisomerase I Inhibitors Market

• 15.1. Western Europe Topoisomerase I Inhibitors Market Overview
• 15.2. Western Europe Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Topoisomerase I Inhibitors Market

• 16.1. UK Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Topoisomerase I Inhibitors Market

• 17.1. Germany Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Topoisomerase I Inhibitors Market

• 18.1. France Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Topoisomerase I Inhibitors Market

• 19.1. Italy Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Topoisomerase I Inhibitors Market

• 20.1. Spain Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Topoisomerase I Inhibitors Market

• 21.1. Eastern Europe Topoisomerase I Inhibitors Market Overview
• 21.2. Eastern Europe Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Topoisomerase I Inhibitors Market

• 22.1. Russia Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Topoisomerase I Inhibitors Market

• 23.1. North America Topoisomerase I Inhibitors Market Overview
• 23.2. North America Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Topoisomerase I Inhibitors Market

• 24.1. USA Topoisomerase I Inhibitors Market Overview
• 24.2. USA Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Topoisomerase I Inhibitors Market

• 25.1. Canada Topoisomerase I Inhibitors Market Overview
• 25.2. Canada Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Topoisomerase I Inhibitors Market

• 26.1. South America Topoisomerase I Inhibitors Market Overview
• 26.2. South America Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Topoisomerase I Inhibitors Market

• 27.1. Brazil Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Topoisomerase I Inhibitors Market

• 28.1. Middle East Topoisomerase I Inhibitors Market Overview
• 28.2. Middle East Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Topoisomerase I Inhibitors Market

• 29.1. Africa Topoisomerase I Inhibitors Market Overview
• 29.2. Africa Topoisomerase I Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Topoisomerase I Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Topoisomerase I Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Topoisomerase I Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Topoisomerase I Inhibitors Market Competitive Landscape
• 30.2. Topoisomerase I Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Nektar Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Topoisomerase I Inhibitors Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. BioNTech SE
• 31.3. Daiichi Sankyo Company Limited
• 31.4. Ipsen Pharma S.A.S.
• 31.5. Purdue Pharma L.P.
• 31.6. Zymeworks Inc.
• 31.7. Sagent Pharmaceuticals Inc.
• 31.8. Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
• 31.9. Debiopharm Group SA
• 31.10. Harbour BioMed Therapeutics Limited
• 31.11. Bio-Thera Solutions Ltd.
• 31.12. Gibson Oncology LLC
• 31.13. TopoGEN Inc.
• 31.14. DualityBio Inc.
• 31.15. Iksuda Therapeutics Ltd.

32. Global Topoisomerase I Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Topoisomerase I Inhibitors Market

34. Recent Developments In The Topoisomerase I Inhibitors Market

35. Topoisomerase I Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Topoisomerase I Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Topoisomerase I Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Topoisomerase I Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer